Ovid Therapeutics (OVID) Cash & Current Investments (2016 - 2026)

Ovid Therapeutics (OVID) has reported Cash & Current Investments for 11 consecutive years, with $117.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash & Current Investments rose 205.68% year-over-year to $117.2 million; the trailing twelve-month figure through Jun 2026 stood at $117.2 million (up 205.68% YoY), and the FY2025 full-year result was $69.6 million, up 31.2% from the prior year.
• Cash & Current Investments retreated to $117.2 million in Q2 2026 per OVID's latest filing, from $155.5 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $168.6 million in Q1 2022 and bottomed at $25.6 million in Q3 2025.
• Historically, Cash & Current Investments has averaged $96.0 million across 5 years, with a median of $93.4 million in 2023.
• The sharpest annual moves came in 2025 and 2026: Cash & Current Investments plunged 59.17% in 2025, then surged 261.71% in 2026.
• Over 5 years, Cash & Current Investments stood at $129.0 million in 2022, then declined by 17.96% to $105.8 million in 2023, then sank by 49.85% to $53.1 million in 2024, then soared by 31.2% to $69.6 million in 2025, then soared by 68.33% to $117.2 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $117.2 million, $155.5 million, and $69.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.